Release time：Aug 26, 2021
Aug 26, 2021, Shanghai - Mabwell (Shanghai) Bioscience Co. Ltd ("Mabwell") and FEGO Biotech Pte Ltd ("FEGO") jointly announced today that the two companies have entered into a cooperation agreement to commercialize Mabwell's 9MW0113, a proposed biosimilar of Adalimumab (Humira?) for Singapore Market.
The partnership includes supply of drug substance with drug product technology. FEGO shall produce the Drug Product and bring it to market by obtaining the necessary regulatory approvals in the country where FEGO holds the commercialization rights of 9MW0113.
9MW0113 is a recombinant human anti-TNF-α monoclonal antibody, which is used to reduce pain and swelling due to certain types of arthritis (such as rheumatoid arthritis). Biosimilars are shown to be similar in safety, efficacy and immunogenicity to the innovator's approved product with the advantage of offering to lower the healthcare expenditure of government and patients.
Under the terms of the agreement, both companies aim to achieve over $60 million in sales upon obtaining market authorization by 2030.
Dr LIM Kah Meng, CEO and principal founder of FEGO Biotech commented that, "We are excited to work with Mabwell in a long-term collaboration and, with this collaboration will expand FEGO's footprint into the Biopharma sector. We are incredibly happy to be able to work with Mabwell team who is committed to make all necessary steps to complete the regulatory process of 9MW0113".
Dr. Datao Liu, CEO and principal founder of Mabwell commented, "We are keen to work with FEGO to bring affordable biosimilar medicines to patients in South-East Asian region and we are also equally excited to work with FEGO on any possible collaborations on their local fill-finish in Singapore by supporting on uninterrupted supplies of Drug substances of this biosimilar and several other future biologics".
About FEGO Biotech
FEGO Biotech is a Singapore-based biotech research company that is focused on immuno-therapy with strong interest in the development of novel drugs and clinically proven cell therapy products. Working closely with identified pharmaceutical partners as well as certain government-backed science agencies to further enhance its medicines to reach markets such as China, India, the US and parts of Europe, APAC and Middle-East. FEGO is also currently involved in immunology field of smart supplement products sold widely in this region and a brand setter.
